Glaukos Corporation company information, Employees & Contact Information

Glaukos Announces FDA Approval of Epioxa™ Business Wire

Glaukos Eyes Growth Opportunities at Wells Fargo Healthcare Conference This September Stock Titan

Earnings call transcript: Glaukos Q2 2025 reports record sales, stock rises Investing.com

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting PharmiWeb.com

FDA Accepts NDA for Epioxa for Keratoconus Treatment HCPLive

RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire VisionMonday.com

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results Business Wire

$80M, 200,000 Sq-Ft Facility: Glaukos Expands U.S. Manufacturing with Massive Alabama Investment Stock Titan

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 PharmiWeb.com

Glaukos Announces First Quarter 2025 Financial Results Business Wire

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution Business Wire

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ Business Wire

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform Business Wire

US FDA approves Glaukos' new eye therapy Reuters

Global ophthalmic pharmaceutical and medical technology company, Glaukos, to locate multimillion-dollar facility in Cummings Research Park City of Huntsville (.gov)

Glaukos receives FDA approval for Epioxa topical therapy for keratoconus Ophthalmology Times

Glaukos breaks ground on high-tech facility in Huntsville, eyes 150 jobs Alabama Department of Commerce

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting Stock Titan

Glaukos Expands To Huntsville With $82 Million Research And Manufacturing Campus Huntsville Business Journal

Glaukos Builds Dual Growth Engines Amid Market Headwinds Yahoo Finance

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks Yahoo Finance

Glaukos breaks ground on new Huntsville campus Business Alabama Magazine

Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS Ophthalmology Times

Glaukos' Pipeline And High Valuation: A Risky Hold With Long-Term Upside (NYSE:GKOS) Seeking Alpha

Glaukos nets European green lights for glaucoma surgery micro-stents Fierce Biotech

Earnings call transcript: Glaukos Corp beats Q1 2025 EPS forecast, stock falls Investing.com

Glaukos reports positive Phase 3 results for Epioxa Ophthalmology Times

Navratil, Glaukos corp officer, sells $453k in shares Investing.com

Glaukos Licenses Iveena’s Investigational Keratoconus Therapy Business Wire

Glaukos Corporation Stock (GKOS) Opinions on Recent Institutional Investments Quiver Quantitative

Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy Ophthalmology Times

Glaukos breaks ground on $80M facility in Alabama Medical Design & Outsourcing

Retina care evolves with latest sustained-release therapeutic agents Healio

Glaukos Corporation: Delivering Consistent Growth (NYSE:GKOS) Seeking Alpha

Glaukos Corporation Sees A Bright Future In Huntsville Huntsville Business Journal

Glaukos’ phase 3 confirmatory trial for Epioxa reaches pipeline enrollment milestone Optometry Times

BLOG: More patients may benefit from cross-linking under anesthesia Healio

Glaukos uses podcast set up for 'Wise Eyes' disease awareness campaign Fierce Pharma

Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry Business Wire

Prostaglandin Analogs Market Size to Hit USD 6.38 Billion by 2034 Precedence Research

Orsini Specialty Pharmacy Selected By Glaukos® Corporation As A Specialty Pharmacy Distribution Partner For Photrexa® And Photrexa® Viscous PR Newswire

Glaukos to exchange $230M in senior notes for common stock MassDevice

MIGS evolution augurs earlier intervention, stand-alone procedures Healio

FDA clears Glaukos’ iPrime Drug Delivery Business

Monitor keratoconus progression after cross-linking treatment Ophthalmology Times

MIGS: Will reimbursement changes stymie innovation? Healio

Device Maker Glaukos Moving HQ to Aliso Viejo Orange County Business Journal

What's New for Your Cataract Procedures Association of periOperative Registered Nurses | AORN

MIGS, premium IOLs, VMT propel optometric care to the next level Healio

Novel Drug Delivery Systems American Academy of Ophthalmology

Glaukos introduces the iprism SX insightnews.com.au